Protein binding in antiretroviral therapies

AIDS Research and Human Retroviruses

Volumn 19, Issue 9, 2003, Pages 825-835

  Boffito, Marta ^a   Back, David J ^b   Blaschke, Terrence F ^c   Rowland, Malcolm ^d   Bertz, Richard J ^e   Gerber, John G ^f   Miller, Veronica ^g  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e ABBOTT LABORATORIES   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g Forum for Collaborative HIV Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALBUMIN; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; OROSOMUCOID; PHENYTOIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; VALPROIC ACID; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG PROTEIN BINDING; EQUILIBRIUM DIALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IC 50; PRIORITY JOURNAL; PROTEIN BINDING; ULTRAFILTRATION; VIRUS REPLICATION; WILD TYPE;

ANIMALS; ANTI-RETROVIRAL AGENTS; BLOOD PROTEINS; DRUG INTERACTIONS; HUMANS; METABOLIC CLEARANCE RATE; PROTEIN BINDING; TISSUE DISTRIBUTION;

EID: 0141481966     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922203769232629     Document Type: Article

References (39)

1. Huisman MT, Smit JW, and Schinkel AH: Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 2000;14:237-242.
2. Gerber J: Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection. Clin Infect Dis 2000;30(Suppl 2):S123-S129.
3. Back DJ, Gatti G, Fletcher C, et al.: Therapeutic drug monitoring in HIV infection: Current status and future directions. AIDS 2002;16(Suppl 1):S5-S37.
4. Hoetelmans RM, Menhorst PL, Mulder JW, Burger DM, Koks CH, and Beijnen JH: Clinical pharmacology of HIV protease inhibitors: Focus on saquinavir, indinavir, and ritonavir. Pharm World Sci 1997;19:159-175.
5. Back DJ: Update and summary on pharmacokinetics [Abstract TurB176]. In: XIVth International AIDS Conference 2002. Barcelona, Spain.
6. 1-acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 1996;40:1491-1497.
7. DuPont Pharmaceuticals: Sustiva [Efavirenz product package insert]. DuPont Pharmaceuticals, Hertfordshire, UK, 1999.
8. Boehringer-Ingelheim International: Viramune [Nevirapine product package insert]. Boehringer-Ingelheim International GmbH, Ingelheim am Rhein, Germany, 1999.
9. Bilello JA and Drusano GL: Relevance of plasma protein binding to antiviral activity and clinical efficacy of inhibitors of human immunodeficiency virus protease. J Infect Dis 1996;173:1524-1526.
10. 1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors SQV, ritonavir and IDV in vitro. Br J Clin Pharmacol 2001;51:99-102.
11. Rowland M: Protein binding and drug clearance. Clin Pharmacokinet 1984;9(Suppl 1):10-17.
12. Rowland M and Tozer TN: Clinical Pharmacokinetics: Concepts and Applications, 3rd Ed. Lippincott Williams & Wilkins, Media, Pennsylvania, 1995, pp. 137-183.
13. Branch RA, Jones J, and Read AE: A study of factors influencing drug disposition in chronic liver disease, using the model drug (+)-propranolol. Br J Clin Pharmacol 1976;3:243-249.
14. Benet LZ and Hoener BA: Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002;71:115-121.
15. Montaner J, Hill A, and Acosta E: Practical implications for the interpretation of minimum plasma concentration/inhibitory concentration ratios. Lancet 2001;375:1438-1440.
16. min/IC ratio: False precision? [Abstract 233]. In 5th International Congress on Drug Therapy in HIV Infection 2000. Glasgow, UK.
17. Molla A, Vasavanonda S, Kumar G, Sham HL, Johnson M, and Grabowski B: Human serum attenuates the activity of protease inhibitors toward wild-type and mutant HIV. Virology 1998;520:255-262.
18. Khoo SH, Hoggard PG, Newton P, et al.: Intracellular accumulation of the protease inhibitor saquinavir (SQV) and indinavir (IDV) - the effect of coadministration with ritonavir (RTV) [Abstract 159]. In: 8th European Conference on Clinical Aspects and Treatment of HIV Infection 2001. Athens, Greece.
19. Nascimbeni M, Lamotte C, Peytavin G, Farinotti R, and Clavel F: Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type-1 protease inhibitors in tissue culture. Antimicrob Agents Chemother 1999;43:2629-2634.
20. Jones K, Hoggard PG, Sales SD, Khoo S, Davey R, and Back DJ: Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. AIDS 2001;15:675-681.
21. Boffito M, Hoggard PG, Reynolds HE, et al.: Unbound saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects. Br J Clin Pharmacol 2002;54:262-268.
22. Anderson PL, Brundage RC, Bushman L, Kakuda TN, Remmel RP, and Fletcher CV: IDV plasma protein binding in HIV-1-infected adults. AIDS 2000;14:2293-2297.
23. Hsu A, Bertz R, Hickman D, et al.: Assessment of plasma protein binding of lopinavir (LPV) and ritonavir (RTV) between in vitro and ex vivo experiments and between HIV-infected patients and HIV-negative healthy volunteers [Abstract 753]. In: 8th Conference on Retroviruses and Opportunistic Infections 2001. Chicago, IL.
24. Boffito M, Hoggard PG, Meaden ER, et al.: Lopinavir/ritonavir protein binding through the 12-hour dosing interval: An in vivo evaluation [Abstract A-1407]. In: 42nd International Conference of Antimicrobial Agents and Chemotherapy 2002. San Diego, California.
25. Herforth C, Stona JA, Jayewardene AL, et al.: Determination of nelfinavir free drug concentrations in plasma by equilibrium dialysis and liquid chromatography/tandem mass spectrometry: Important factors for method optimization. Eur J Pharm Sci 2002;15:185-195.
26. 1-acid glycoprotein reduces the volume of distribution and systemic clearance of SQV. Drug Metab Dispos 2001;29:299-303.
27. Almond LM, Boffito M, Hoggard PG, et al.: Nevirapine protein binding in HIV infected individuals [Abstract P164]. In: 6th International Congress on Drug Therapy and HIV Infection 2002. Glasgow, UK.
28. Lindup WE: Plasma protein binding of drugs - some basic and clinical aspects. In: Progress in Drug Metabolism (Bridges JW, Chasseaud LF, and Gibson GG, eds.). Taylor & Francis, London, UK, 1987, pp. 141-185.
29. 1-acid glycoprotein in health and disease. Pharm Rev 1988;40:1-47.
30. 1-Acid glycoprotein levels in AIDS patients before and after short-term treatment with zidovudine (ZDV). J Acquir Immune Defic Syndr 1993;5:531-533.
31. 1-Acid glycoprotein concentrations in HIV disease: Implications for treatment with protease inhibitors. AIDS 1996;10:S24.
32. Piafsky KM: Disease-induced changes in the plasma binding of basic drugs. Clin Pharmacokinet 1980;5:246-262.
33. 1-Acid glycoprotein and binding of basic drugs. Methods Find Exp Clin Pharmacol 1983;5:635-648.
34. Blaschke TF: Protein binding and kinetics of drugs in liver disease. Clin Pharmacokinet 1977;2:32-44.
35. 1 Acid glycoprotein levels in humans immunodeficiency virus-infected subjects on antiretroviral regimens. Drug Metab Dispos 2002;30:859-860.
36. 1 acid glycoprotein: Generation of a three-dimensional quantitative structure-activity relationship model for drug binding to the A variant. Mol Pharmacol 1998;54:129-138.
37. Rolan PE: Plasma protein binding displacement interactions: Why are they still regarded as clinically important? Br J Clin Pharmacol 1994;37:125-128.
38. Simons FE, Rigatto H, and Simons KJ: Pharmacokinetics of theophylline in neonates. Semin Perinatol 1981;5:337-345.
39. 50 for lopinavir and ritonavir: A useful measure for the estimation of inhibitory quotients into plasma and sanctuary sites [Abstract 3.3]. In: 3rd International Workshop on Clinical Pharmacology of HIV Therapy, 2002. Washington, DC.